RICHMOND, Calif., Aug. 30, 2018 /PRNewswire/ -- Sangamo
Therapeutics, Inc. (Nasdaq: SGMO) announced today that management
will host a conference call on September
5th at 9:00 a.m. ET
to discuss clinical data from the CHAMPIONS Study, the Company's
Phase 1/2 trial evaluating SB-913 in vivo genome editing
therapeutic candidate for MPS II. The call will follow the
presentation of the data earlier that day at the 2018 Symposium of
the Society for the Study of Inborn Errors of Metabolism in
Athens, Greece.
Sangamo also announced today that management will participate in
the following healthcare investor conferences in September.
- 2018 Wells Fargo Healthcare Conference, Boston, MA, September
5-6, 2018
Sangamo's presentation is
scheduled for 9:10 a.m. ET on
Thursday, September 6th.
The Wells Fargo presentation will
be webcast live and may be accessed via a link on the Sangamo
Therapeutics website in the Investors and Media section under
Events and Presentations. The presentation will be archived on the
Sangamo website for two weeks after the event.
- Bank of America Merrill Lynch Global Healthcare Conference
2018, London, UK, September 11-14, 2018
Sangamo's presentation is
scheduled for 3:25 p.m. BST on
Wednesday, September 12th.
Webcasting services are not
provided at the Bank of America Merrill Lynch conference.
SB-913 Conference Call
Sangamo will host a conference call on September 5, 2018, at 9:00
a.m. ET, which will be open to the public. The call will
also be webcast live and can be accessed via a link on the Sangamo
Therapeutics website in the Investors and Media section under
Events and Presentations.
The conference call dial-in numbers are (877) 377-7553 for
domestic callers and (678) 894-3968 for international callers. The
conference ID number for the call is 8798741. For those unable to
listen in at the designated time, a conference call replay will be
available for one week following the conference call. The
conference call replay numbers for domestic and international
callers are (855) 859-2056 and (404) 537-3406, respectively. The
conference ID number for the replay is 8798741.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc. is focused on translating
ground-breaking science into genomic therapies that transform
patients' lives using the Company's platform technologies in genome
editing, gene therapy, gene regulation and cell therapy. For more
information about Sangamo, visit www.sangamo.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/sangamo-therapeutics-announces-conference-call-to-review-sb-913-champions-study-data-and-participation-at-upcoming-investor-conferences-300704736.html
SOURCE Sangamo Therapeutics, Inc.